

## DAFTAR PUSTAKA

1. Mitra SP. Arthritis: Classification, Nature & Cause - A Review. *AJBBL*. 2013;2(3):2-5
2. Badan Penelitian dan Pengembangan Kesehatan. Laporan Riset Kesehatan Dasar. Jakarta; 2018.
3. Dinas Kesehatan Provinsi Sumatera Barat. Profil Kesehatan Sumatera Barat 2013-2017. Padang; 2018.
4. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug – drug interactions with over-the-counter NSAIDs. *Dove Press Journal*. 2015;11:1061–75.
5. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk?. *Drugs*. 2004;64(23):2619–27.
6. Roth SH. Coming to Terms with Nonsteroidal Anti-Inflammatory Drug Gastropathy. *Drugs*. 2012;72 (7):873-879.
7. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. *Am Journal Gastroenterol*. 1987 Nov;82(11):1153–8.
8. Suyata BE, Bardiman S, Bakry F. A Comparison of Efficacy between Rebamipide and Omeprazole in the Treatment of NSAID Gastropathy. *The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy*. 2004;5 (3): 89-94.
9. Muhammad EP, Murni AW, Sulastrri D, Miro S. Hubungan Derajat Keasaman Cairan Lambung dengan Derajat Dispepsia pada Pasien Dispepsia Fungsional. *JKA*. 2016;5(2):371–4.
10. Valle JD. Peptic Ulcer Disease and Related Disorders. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, eds. *Harrison's Principle of Internal Medicine*. 17th ed. New York : McGrawHill. 2008;1855-1857.
11. Shelia C. Prevalensi Gastropati Obat Anti Inflamasi Non Steroid Di RSUP Haji Adam Malik Medan Pada Periode Juli–Desember 2012. *Skripsi*. 2012;1-32.
12. Louet M, Labbé CM, Fagnen C, Aono CM, Homem-de-Mello P, Villoutreix BO, et al. Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9/30. *PLoS One*. 2018;13(5):6–8.

13. Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: Functional and clinical considerations. *Journal of Personalized Medicine*. 2018;8(1):1– 31.
14. Ma J, Yang XY, Qiao L, Liang LQ, Chen MH. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy. *Journal of Digestive Disease*. 2008;9(2):79–83.
15. Estany-Gestal A, Salgado-Barreira A, Sánchez-Diz P, Figueiras A. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: A systematic critical review. *Pharmacogenet Genomics*. 2011;21(7):357–64.
16. Kemuning MC. Gambaran Varian Gen CYP2C9 rs1057910 Pada Pasien Arthritis Etnis Minangkabau yang Mempunyai Efek Samping Pada Saluran Cerna Akibat Penggunaan OAINS.Skripsi. 2019;52-53.
17. Gusriadi AR. Gambaran Varian Gen CYP2C9 rs1799853 Pada Pasien Arthritis Etnis Minangkabau yang Mempunyai Efek Samping Pada Saluran Cerna Akibat Penggunaan OAINS.Skripsi. 2019;63.
18. Suari BA, Ihsan M, Burhanuddin L. Gambaran Penderita Osteoarthritis di Bagian Bedah RSUD Arifin Achmad Periode Januari 2011 – Desember 2013. *Jurnal Online Mahasiswa FK*.2015;2(2):1.
19. Pratiwi AI. Diagnosis and Treatment Osteoarthritis. *Majority*.2015;4(4):13-16.
20. Arovah NI. Fisioterapi dan Terapi Latihan Pada Osteoarthritis. *Medikora*. 2007;3(1):22-23
21. Ong CKS, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs.*Clinical Medicine & Research*. 2007;5(1):19–34.
22. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. *Expert Opinion on Drug Safety* .2009;8(6):669–81.
23. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of. *The Journal of Pharmacy and Pharmaceutical Sciences*. 2013;16(5):821–47.
24. Champion GD, Graham GG. Pharmacokinetics of non-steroidal antiinflammatory agents. *New Zealand Medical Journal*.1978;8(1):94–100.
25. Katzung BG, Francisco S, Akporiaye ET, Aminoff MJ, Francisco S, Basbaum AI, et al. *Basic and Clinical Pharmacology*. 10th ed. Hill MG;2006. 1179 p.

26. Ionescu C, CAIRA MR. Drug Metabolism. Ionescu C, Caira MR, editor. Berlin/Heidelberg: Springer-Verlag; 2005.29-37p
27. Yiannakopoulou E. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: Clinical implications. *The European Journal of Clinical Pharmacology*. 2013;69(7):1369–73.
28. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. *Biochemical Pharmacology*. 1997;54(1):33–41.
29. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmüller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. *The British Journal of Clinical Pharmacology*. 2003;55(1):51–61.
30. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. *Biochimica et Biophysica Acta*. 2007;1770(3):489–94.
31. He S-M, Zhou Z-W, Li X-T, Zhou S-F. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. *Current Medicinal Chemistry*. 2011;18(5):667–713.
32. Werner U. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. *Clinical Pharmacology and Therapeutics*. 2003;74(2):130–7.
33. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. *Pharmacogenetics*. 2001;11(3):223–35.
34. Nabeel HB, Daniel EF. Nonsteroidal Anti-Inflammatory Drugs, DiseaseModifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout. In: Medical M-H, editor. *Basic and Clinical Pharmacology*. 10th ed. New York; 2007. 573–598p.
35. Chen Y, Kuehl GE, Bigler J, Rimorin CF, Schwarz Y, Shen DD, et al. UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. *Pharmacogenetic and Genomics*. 2007;17(8):571–9.
36. Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. *Pharmacogenetics*. 2000;10(6):511–8.

37. Brenner SS, Herrlinger C, Dilger K, Murdter TE, Hofmann U, Marx C, et al. Influence of Age and Cytochrome P450 2C9 Genotype on the SteadyState Disposition of Diclofenac and Celecoxib. *Clinical Pharmacokinetic*. 2003;42(3):283–92.
38. Tracy TS, Matthew Hutzler J, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9\*3 and CYP2C9\*5) and the F114L active site mutation of CYP2C9: Effect on atypical kinetic metabolism profiles. *Drug Metabolism and Disposition*. 2002;30(4):385–90.
39. Agúndez JA, García-Martín E, Martínez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? *Expert Opinion on Drug Metabolism Toxicology*. 2009;5(6):607–20.
40. Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. *Drug Metabolism and Disposition*. 1998;26(3):261–6.
41. Relling MV, Giacomini. Pharmacogenomics. In: Goodman & Gilman's *The Pharmacological Basis of Therapeutic*. 12th ed. Brunton L, Chabner B, Knollman B, editor. New York: McGraw-Hill, 2011. 849–874p.
42. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. *Biochemical Pharmacology*. 1997;54(1):33–41.
43. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmöller J. Enantiospecific effects of cytochrome p450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. *Clinical Pharmacology and Therapeutic*. 2002;72(1):62–75.
44. Crespi CL, Miller VP. The R144C change in the CYP2C9\*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. *Pharmacogenetics*. 1997;7:203–10.
45. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9(\*)3 allele. *Pharmacogenetics*. 1999;9:71–80.
46. Zhou S-F, Zhou Z-W, Yang L-P, Cai J-P. Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development. *Current Medicinal Chemistry*. 2009;16(27):3480–675.

47. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9\*3. *Pharmacogenetics*. 1997;7:361–7.
48. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. *Clinical Pharmacology and Therapeutic*. 2004;76(1):18–26.
49. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates. *Pharmacogenetics*. 2000;10(2):95–104.
50. Djodjodiningrat D. Dispepsia Fungsional. In: *Buku Ajar Ilmu Penyakit Dalam Jilid II*. 6th ed. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2014. 1729–1736 p.
51. Schmidt-Martin D, Quigley E. The Definition of Dyspepsia. In: *Dyspepsia In Clinical Practice*. Duvnjak M, editor. New York: Springer; 2011;1-55p.
52. Stanghellini V. Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. *Digestive Disease*. 2018;35(1):14–7.
53. Shin CM, Huh KC. Diagnosis and treatment of functional dyspepsia. *Journal of the Korean Medical Association*. 2016;59(4):311–8.
54. Montellano PRO de. *Cytochrome P450 Structure, Mechanism, and Biochemistry*. 2nd ed. Montellano PRO de, editor. New York: Plenum Press; 1995. 183p.
55. González-Ponce HA, Rincón-Sánchez AR, Jaramillo-Juárez F, Moshage H. Natural dietary pigments: Potential mediators against hepatic damage induced by over-the-counter non-steroidal anti-inflammatory and analgesic drugs. *Nutrients*. 2018;10(2):1–39.
56. Shakunthala N. New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome. *Expert Opinion on Drug Metabolism Toxicology*. 2010;6(1):1–15.
57. Isvoran A, Louet M, Vladiu DL, Craciun D, Loriot M-A, Villoutreix BO, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. *Drug Discovery Today*. 2017;22(2):366–76.
58. Zhang H-F, Wang H-H, Gao N, Wei J-Y, Tian X, Zhao Y, et al. Physiological Content and Intrinsic Activities of 10 Cytochrome P450 Isoforms in Human Normal Liver Microsomes. *Journal Pharmacology Experimental Therapeutic*. 8 Juni 2016;358(1):83–93.

59. Niwa T, Yamazaki H. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition. *Current Drug Metabolism*.2012;13(8):1145–59.
60. Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. *Drug Metabolism Pharmacokinetic*. 2013;28(1):28–37.
61. Veldhuyzen van Zanten SJO, Tytgat KMAJ, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and *Helicobacter pylori* associated gastritis? *J Clin Epidemiol* 1993; 46: 273-9.
62. O'Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. *Clinical Pharmacology Therapeutic*. 1987;42(3):290–4.
63. Zilly W, Breimer DD, Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. *European Journal of Clinical Pharmacology*.1975;9(2–3):219–27.
64. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampin drug interaction in humans. *Clinical Pharmacology Therapeutic*.1987;42(4):388–94.
65. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, SydowBäckman M, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. *Proceedings of the National Academy of Sciences of the United States of America*.1998;95(21):12208–13.
66. Wyatt JE, Pettit WL, Harirforoosh S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. *Pharmacogenomics Journal*. 2012;12(6):462–7.
67. Pilotto A, Franceschi M, Vitale DF, Zaninelli A, et al. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. *Aliment Pharmacol Therapeutic*. 2005;22(2):147–55.
68. Ramakrishnan K, Salinas RC. Peptic ulcer disease. *Am Fam Physician*. 2007;76(7):1005–12.
69. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, et al. Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms. *Gastroenterology*. 2007 Aug;133(2):465–71.

70. Spiegel BMR, Chiou C-F, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: Cost-effectiveness of competing strategies in varying risk groups. *Arthritis Rheumatism*.2005;53(2):185–97.
71. Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.*Journal of Pharmacology*. 2004 Jan;141(2):205–8.
72. Shiotani A, Sakakibara T, Nomura M, Yamanaka Y, Nishi R, Imamura H, et al. Aspirin-induced peptic ulcer and genetic polymorphisms. *J Gastroenterol Hepatol*. 2010;25(SUPPL. 1):25–8.
73. Vonkeman HE, van de Laar MA, van der Palen J et al. Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. *Clin. Ther*. 2006; 28: 1670–6
74. Mohammed Y, Narayana S, Arun HS.A Comparative Study of Efficacy and Safety of Piroxicam and Naproxen in the Management of Pain in Osteoarthritis of the Knee. *Journal of Natural Science, Biology and Medicine*.2018;9(2):180-4.
75. Hendera, Suryana BPP, Yulistiani.Gastrointestinal Tolerability of Diclofenac Sodium And Meloxicam In Osteoarthritis Patient.*Folia Medica Indonesiana*.2015;51(1):35-39.
76. Roman-Blas J, Castañeda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. *Arthritis Research & Therapy*. 2009;11(5):241.
77. Kementrian Kesehatan. KEPMENKES Nomor 328/ MENKES/ SK/ VIII/ 2013 tentang Formularium Nasional. 2013.
78. Roth SH.Diclofenac In The Treatment of Osteoarthritis. *International Journal of Clinical Rheumatology*.2013;8(2):185-203.
79. Mutschler E. *Dinamika Obat*. 5th ed. Mathilda B, Widiyanto, Ranti AS, translator. Bandung: ITB, 1991. 922p.
80. Lee A. *Adverse drug reactions*. 2nd ed. London: Pharmaceutical Press; 2006.125-56p.
81. Purwadi FV, Rostinawati T. Review: Pengaruh Polimorfisme CYP2C9\*2 dan CYP2C9\*3 Terhadap Risiko Pendarahan Saluran Gastrointestinal Terapi NSAID.*Farmaka*.2016;14(2):264-72.

82. Burke A, Smyth E, Fitzgerald GA: Analgesic Antipyretic Agent, Pharmacotherapy of Gout S. In: Brunton LL, Lazo JS, Parker KL. Goodman and Gillman's the Pharmacological Basis of Therapeutics. 11th ed. USA: The McGraw-Hill Companies; 2006.398-429p.
83. Waranugraha Y, Suryana BPP, Pratomo B. Hubungan Pola Penggunaan OAINS dengan Gejala Klinis Gastropati pada Pasien Reumatik. *Jurnal Kedokteran Brawijaya*.2010;26(2):107-12.
84. Lestari D. Hubungan Lama Penggunaan Obat Antiinflamasi Nonsteroid Dengan Gejala Klinis Dispepsia Pada Penderita Osteoarthritis Berdasarkan Gastrointestinal Symptom Score. *Electronic Thesis And Dissertation Unsyiah*.2016;28-33.
85. Bibi Z. Role of cytochrome P450 in drug interactions. *Nutrition & metabolism*. 2008;5(27):1-10
86. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. *Pharmacogenetics and Genomics*. 2002;12(4):251-63.
87. Hatta FH, Lundblad M, Ramsjo M, Kang JH, Roh HK, Bertilsson L, Eliasson E, Aklillu E. Differences in CYP2C9 genotype and enzyme activity between Swedes and Koreans of relevance for personalized medicine: Role of ethnicity, genotype, smoking, age, and sex. *Omics: a journal of integrative biology*. 2015;19(6):346-53.
88. Figueiras A, Estany-Gestal A, Aguirre C, Ruiz B, Vidal X, Carvajal A, Salado I, Salgado-Barreira A, Rodella L, Moretti U, Ibáñez L. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. *Pharmacogenetics and genomics*. 2016;26(2):66.